|
|
 |
 |
Selected indications and products:
|
 |
|
 |
|
|
|
 |
Scheduled omnibus studies:
|
|
|
|
|
|
|
| Analysis of competing drugs |
|
|
The analysis of competing drugs is one of the most challenging tasks in market research. Bioscience Market Research describes marketed drugs by a set of attributes related to efficacy, safety, tolerability, formulation, brand name, and price. The attributes are expressed at different levels. For example, the formulation attribute 'application frequency' may have two levels: 'once a day' and 'three times a day'. A critical task is to understand why some drugs successfully penetrate the market while others do not. Often this is not obvious, and market success or failure may be related as much to efficacy and formulation as to promotion and marketing effort. Among other methods, Bioscience Market Research also uses multiple regression algorithms in order to identify relevant drivers of success.
Even more challenging is the review of potentially competing drugs that are still in development. Bioscience Market Research, in collaboration with its affiliate  Bioscience Valuation, has in-depth expertise in evaluating scientific approaches and is well positioned to assess the merits of alternative mechanisms of drug action. This enables us to evaluate the competitive threat of almost any innovative approach for the benefit of our clients. Furthermore, we have access to various databases that provide us with up-to-date information about the most recent status of the developmental stage of competing drugs. All information gathered can be used to feed our proprietary TPCASM Target Profile Conjoint Analysis and DMMSM Dynamic Market Modeling assessment tools.
Epidemiology and patient flow
Primary and secondary market research
Analysis of competing drugs
TPCASM (Target Profile Conjoint Analysis)
DMMSM (Dynamic Market Modeling) |
 |
|
